Campath-1h

Hale, G., Dyer, M.J.S., Clark, M.R., et al. (1988). Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2, 1394-1399. 

D. S. Ashton, C. R. Beddell, D. J. Cooper, and A. C. Lines, Determination of carbohydrate heterogeneity in the humanised antibody CAMPATH 1H by liquid chromatography and matrix-assisted laser desorption ionisation mass spectrometry, Anal. Chim. Acta, 306 (1995) 43 18. 

CDw52, a 21- to 28-kDa phosphatidylinositol-linked glycoprotein of unclear function, is widely expressed on the cell surface of both B and T lymphocytes (187). Anti-CDw52 mAbs include CAMPATH-1 and its humanized version CAMPATH-1H (187-188). CAMPATH-IH has been evaluated in multiple clinical trials, in which it has shown anticancer efficacy against a variety of lymphoid neoplasms (188-190). However, CAMPATH-IH also induced rapid depletion of both B cells and T cells, resulting in potentially profound immunosuppression (191). 

Pruzanski, W., Urowitz, M. B., Grouix, B., and Vadas, P. (1995). Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis. /. Rheumatol. 22, 1816-1819. 

Osborne WL, Lennard AL Acute renal failure and disseminated Intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarablne, Haematologica 2005,90 ECR05... 

---